NCT06003270 - Biological Effects of Quercetin in COPD Phase II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

February 15, 2025

Study Completion Date

July 31, 2025

Conditions

Chronic Obstructive Pulmonary DiseaseEmphysemaChronic Bronchitis With Airway Obstruction

Interventions

DRUG

Quercetin 1000 mg

Active comparator

DRUG

Quercetin 500 MG

Active comparator

DRUG

Placebo

Placebo comparator

Trial Locations (1)

RECRUITING

Nathaniel Marchetti, Philadelphia

All Listed Sponsors

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

Quercegen Pharmaceuticals

INDUSTRY

lead

Temple University

OTHER